[1] LAWSON DH.Pharmacovigilance in the 1990s[J]. Br J Clin Pharmacol, 2003, 44(2): 109-110. [2] SZARFMAN A, MACHADO SG, O’NEILL RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database[J]. Drug Saf, 2002, 25(6): 381-392. [3] ARNAUD M, BÉGAUD B, THURIN N, et al. Methods for safety signal detection in healthcare databases: a literature review[J]. Expert Opin Drug Saf, 2017, 16(6): 721-732. [4] PHAM M, CHENG F, RAMACHANDRAN K.A comparison study of algorithms to detect drug-adverse event associations: frequentist, bayesian, and machine-learning approaches[J]. Drug Saf, 2019, 42(6): 743-750. [5] BATE A, EVANS SJ.Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf, 2009, 18(6): 427-436. [6] BATE A, LINDQUIST M, EDWARDS IR, et al.A bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol, 1998, 54(4): 315-321. [7] RASCHI E, MAZZARELLA A, ANTONAZZO IC, et al.Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the fda adverse event reporting system[J]. Target Oncol, 2019, 14(2): 205-221. [8] CANDORE G, JUHLIN K, MANLIK K, et al.Comparison of statistical signal detection methods within and across spontaneous reporting databases[J]. Drug Saf, 2015, 38(6): 577-587. [9] DUMOUCHEL W, RYAN PB, SCHUEMIE MJ, et al.Evaluation of disproportionality safety signaling applied to healthcare databases[J]. Drug Saf, 2013, 36(Suppl 1): 123-132. [10] VAN PUIJENBROEK EP, BATE A, LEUFKENS HG, et al.A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10. [11] HARPAZ R, DUMOUCHEL W, LEPENDU P, et al.Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system[J]. Clin Pharmacol Ther, 2013, 93(6): 539-546. [12] MATSUSHITA Y, KURODA Y, NIWA S, et al.Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer[J]. Drug Saf, 2007, 30(8): 715-726. [13] YE XF.Progress and thinking of signal detection methodology on post-marketing adverse drug reaction surveillance[J]. Academic Journal of Naval Medical University(海军军医大学学报), 2022, 43(2): 117-122. [14] BAE JH, BAEK YH, LEE JE, et al.Machine learning for detection of safety signals from spontaneous reporting system data: example of nivolumab and docetaxel[J]. Front Pharmacol, 2020, 11: 602365. [15] KIM DW, TISEO M, AHN MJ, et al.Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial[J]. J Clin Oncol, 2017, 35(22) : 2490-2498. [16] AHMAD SR.Adverse drug event monitoring at the Food and Drug Administration[J]. J Gen Intern Med, 2003, 18(1): 57-60. [17] HARPAZ R, ODGERS D, GASKIN G, et al.A time-indexed reference standard of adverse drug reactions[J]. Sci Data, 2014, 1: 140043. [18] WAHAB IA, PRATT NL, WIESE MD, et al.The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection[J]. Pharmacoepidemiol Drug Saf, 2013, 22(5): 496-502. [19] HOANG T, LIU J, ROUGHEAD E, et al.Supervised signal detection for adverse drug reactions in medication dispensing data[J]. Comput Methods Programs Biomed, 2018, 161: 25-38. [20] ARKU D, YOUSEF C, ABRAHAM I.Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning[J]. Expert Opin Drug Saf, 2022: 1235-1238. [21] SHALEV-SHWARTZ S, BEN-DAVID S.Understanding machine learning. From theory to algorithms[M]. Cambridge: Cambridge University Press, 2013. [22] ALVAREZ-REQUEJO A, CARVAJAL A, BéGAUD B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system[J]. Eur J Clin Pharmacol, 1998, 54(6): 483-488. [23] HAUBEN M, ARONSON JK, FERNER RE.Evidence of misclassification of drug-event associations classified as gold standard ‘negative controls’ by the Observational Medical Outcomes Partnership (OMOP)[J]. Drug Saf, 2016, 39(5): 421-432. |